
A Recombinant PNGase F for the Analysis of Glycoproteins

Michael M. Rosenblatt, Chris Hosfield, Laurie Engel, Gary Kobs, and Marjeta Urh **Promega Corporation, Madison WI** Ravi Amunugama, David Allen, Michael Ford, and Richard Jones MS Bioworks LLC , Ann Arbor MI

Introduction

endoglycosidase first isolated PNGase F is an Flavobacterium meningosepticum. It is a 34 kDa enzyme with specificity for N-linked glycan removal. Given the difficulty of MS/MS-based sequencing of glycopeptides, upstream removal of glycan-chains by PNGase F is a powerful tool for proteomics research.

We have expressed PNGase F as a HaloTag[™] fusion and purified it to homogeneity. Recombinant PNGase F is highly active and was shown to remove N-linked glycans from a wide panel of substrates including human serum glycoproteins. Furthermore, the enzyme is active under non-denaturing conditions and therefore compatible with MS workflows.




<u>2. PNGase F Enzymatic Assays</u>

A. Purified Glycoprotein Substrates


In a typical experiment, 50 µg of substrate was denatured by heating to 95°C for 10 minutes in 0.5% SDS + 40 mM DTT. Denatured substrate was diluted 2-fold into a final reaction buffer of 50 µL containing 1% NP-40 and 50 mM phosphate buffer, pH = 7.5. Reactions were initiated with PNGase F (500 – 2500 units) and deglycosylation was allowed to proceed for 4-18 hours at 37°C. Samples were analyzed by either SDS-PAGE (Gel-shift) or LC-MS/MS.

B. Human Serum



Human serum (1 mg) was depleted of albumin and IgG (Qiagen). Glycoproteins were enriched using a combined ConA/WGA lectin column. Glycopeptides were enriched by first digesting depleted human serum samples (0.2 mg) with trypsin followed by lectin enrichment. Glycopeptides were desalted with a 50 mg tC₁₈ SEP-PAK cartridge (Waters), lyophilized and reconstituted in PNGase deglycosylation buffer. PNGase F (~1000 U) was added to the test samples while water was added to the controls.





LC-MS/MS




Figure 1. SDS-PAGE analysis of selected protein substrates treated with PNGase F, native and recombinant. Native and recombinant PNGase F effectively Deglycosylated all substrates tested.




Figure 2. RNase B (100 µg) was denatured and treated with immobilized HaloTag-PNGase F, (soluble) HaloTag-PNGaseF or native PNGase F at 37°C for the indicated times. Samples (5 µg) were analyzed by SDS-PAGE and visualized with SimplyBlue stain.

Analysis using LC-MS/MS




Figure 3. Specific examples of deglycosylated peptides prepared using (A) Soluble recombinant PNGase F, (B) immobilized PNGase F or (C) Native PNGase F.

www.promega.com

PNGase F Deglycosylates Serum Proteins






Figure 4. Enriched glycoproteins from human serum were treated with recombinant or native PNGase F at 37°C for 18 hours. Samples were analyzed by SDS-PAGE and visualized with SimplyBlue stain (A) or with Pro-Q Emerald™ glycoprotein stain (B). Arrows indicate deglycosylated proteins (yellow), recombinant (orange) and native (red) PNGase F. Deglycosylation patterns are virtually identical.

LC-MS/MS analysis of PNGase F treated Serum

Haptoglobin (Untreated) (A)

MSALGAVIAL	LLWGQLFAVD	SGNDVTDIAD	DGCPKPPEIA	HGYVEHSVRY	Q C K N Y Y K <mark>l r t</mark>
			G <mark>С</mark> Р К Р Р Е І А Н		
					G S F P WQ A H M V
SHHNLTTGAT					
			DYAEVGRVGY		
L P V A D Q D Q C I	RHYEGSTVPE	K K T P K <mark>s p v g v</mark>	<mark>q</mark> p i l <mark>n</mark> e h t f <mark>c</mark>	A G <mark>M</mark> S K Y <mark>Q</mark> E D T	<mark>C</mark> Y G D A G S A F A
VHDLEEDTWY	A T G I L S F D K S	CAVAEYGVYV	KVTSIQDWVQ	KTIAEN	

Haptoglobin (PNGase F treated)

	MSALGAVIAL	<u>l l wgq l f a v d</u>	SGNDVTDIAD	DGCPKPPEIA	<u>h g y v e h s v</u> r y	QCKNYY <mark>klrt</mark>
		K K Q W I N K A V G				
	<u>g d g v y t l <mark>n</mark> n e</u>	KQ WINKAVG D	K L P E <mark>C</mark> E A V <mark>C</mark> G	<mark>k pk</mark> npanpvq	R <mark>i l g g h l d a k</mark>	G S F P WQ A I M V
		LINEOWLLTT				
	N Y S Q V D I G L I	<mark>k</mark> lk <mark>qkvsvne</mark>	R V M P I C L P S K	D Y A E V G R V G Y	<mark>V S G WG R</mark> N A N F	K <mark>F T D H L K Y V M</mark>
		RHYEGSTVPE				<mark>C</mark> Y G D A G S A F A
	VHDLEEDTWY	A T G I L S F D K S	<mark>C</mark>	<u>KVTSIQDWVQ</u>	<mark>k</mark> tiaen	
_			v44 - 2H			




Figure 5. MS Analysis of Serum samples. (A) The sequence coverage of untreated Haptoglobin is unchanged relative to the PNGase F sample with the only exception being the identification of the glycopeptide whose spectrum is shown is panel (B). Panel (C) shows that in all cases PNGase F treatment significantly increases spectral counts for the deamidated peptides (2-5 fold)

Conclusions

- Recombinant PNGase F has been purified using HaloTag[®] technology to homogeneity.
- \succ Recombinant PNGase F is fully active against both purified glycoprotein substrates and human serum glycoproteins as compared with native PNGase F.
- > PNGase F improves sequence coverage is required to identify glycosylation sites.
- > Deglycosylation of serum using PNGase F is compatible with MS workflows (i.e. can be used with non-denaturing buffers).
- Immobilization of PNGase F might be a useful tool for automation of sample prep workflows.



